Literature DB >> 7777571

Blockade of T- and B-lymphocyte development by antibody to the gamma c subunit of the receptors for interleukins 2, 4, and 7.

Y W He1, R B Levy, T R Malek.   

Abstract

Cytokines are important regulators of hematopoesis. Mutations in gamma c, which is a subunit shared by the receptors for interleukin (IL) 2, IL-4, and IL-7, have been causally associated with human X chromosome-linked severe combined immunodeficiency disease. This finding indicates a mandatory role for cytokine receptor signaling at one or more stages of lymphocyte development. To evaluate the cellular level at which gamma c is critical for lymphopoiesis, the effect of monoclonal antibodies to gamma c on the capacity of syngeneic bone marrow cells to reconstitute the hematopoietic compartment of lethally irradiated recipient mice was examined. We show that monoclonal antibody to gamma c blocked lymphocyte development at or before the appearance of pro-B cells and prior to or at the seeding of the thymus by precursor cells while erythromyeloid cell development was normal. These results suggest that one level of lymphocyte development that requires gamma c is a point in hematopoietic cell differentiation near the divergence of lymphopoiesis and erythromyelopoesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777571      PMCID: PMC41762          DOI: 10.1073/pnas.92.12.5689

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Authors:  O Leo; M Foo; D H Sachs; L E Samelson; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

2.  Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

Authors:  M E Conley; A Lavoie; C Briggs; P Brown; C Guerra; J M Puck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Cloning of the gamma chain of the human IL-2 receptor.

Authors:  T Takeshita; H Asao; K Ohtani; N Ishii; S Kumaki; N Tanaka; H Munakata; M Nakamura; K Sugamura
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

4.  In utero treatment with monoclonal antibody to IL-2 receptor beta-chain completely abrogates development of Thy-1+ dendritic epidermal cells.

Authors:  T Tanaka; Y Takeuchi; T Shiohara; F Kitamura; Y Nagasaka; K Hamamura; H Yagita; M Miyasaka
Journal:  Int Immunol       Date:  1992-04       Impact factor: 4.823

5.  Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain.

Authors:  X Cao; E W Shores; J Hu-Li; M R Anver; B L Kelsall; S M Russell; J Drago; M Noguchi; A Grinberg; E T Bloom
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

6.  Activation of T lymphocytes through the Ly-6 pathway is defective in A strain mice.

Authors:  T R Malek; E M Shevach; K M Danis
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

7.  Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.

Authors:  M S Jones; R Riley; B L Hamilton; J Paupe; D Perez; R B Levy
Journal:  Bone Marrow Transplant       Date:  1994-11       Impact factor: 5.483

8.  Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.

Authors:  H Schorle; T Holtschke; T Hünig; A Schimpl; I Horak
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

9.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow.

Authors:  R R Hardy; C E Carmack; S A Shinton; J D Kemp; K Hayakawa
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

10.  Essential role of the interleukin 2-interleukin 2 receptor pathway in thymocyte maturation in vivo.

Authors:  L Tentori; D L Longo; J C Zuñiga-Pflucker; C Wing; A M Kruisbeek
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.